IMG-007 for Alopecia Areata
Recruiting1 awardPhase 1 & 2
Lomita, California
This trial is testing a new medicine called IMG-007 to see if it is safe and effective for adults with significant hair loss due to Alopecia Areata. The medicine likely helps protect hair follicles from immune system attacks, allowing hair to grow back.
Procedure
ADX-914 for Severe Alopecia Areata
Recruiting0 awardsPhase 2
Houston, Texas
This trial tests ADX-914, an injectable medication, in adults with severe hair loss due to Alopecia Areata. The treatment likely works by calming the immune system to help hair grow back. Delgocitinib has shown effectiveness in other inflammatory skin conditions and is being explored for its potential in treating alopecia areata.
Dihydroorotate Dehydrogenase Inhibitor
Farudodstat Tablets for Alopecia Areata
Recruiting0 awardsPhase 2
Fountain Valley, California
This trial is testing farudodstat, a medication that may help people with significant hair loss due to Alopecia Areata. The study focuses on adults who have lost 30% or more of their scalp hair. Farudodstat works by influencing body processes that control hair growth.
Scalp Cooling for Breast Cancer
Recruiting1 awardPhase 2
Boston, Massachusetts
This trial is testing if the Paxman Scalp Cooling System can prevent hair loss in people with advanced breast cancer who are receiving specific treatments. The cooling system works by lowering the scalp temperature to protect hair from the effects of these treatments. The Paxman Scalp Cooling System has been studied in multiple trials and shown to be effective in reducing treatment-induced hair loss in breast cancer patients.
Popular Filters
Trials for Alopecia Patients
Janus Kinase (JAK) Inhibitor
Upadacitinib for Severe Alopecia Areata
Recruiting1 awardPhase 3
Peterborough, Ontario
This trial is testing upadacitinib, a medication that may help people with severe hair loss due to alopecia areata. The drug works by stopping the immune system from attacking hair roots. Adolescents and adults with severe alopecia areata are participating to see if this treatment is safe and effective.
Monoclonal Antibodies
Dupilumab for Alopecia Areata
Recruiting0 awardsPhase 2
Irvine, California
This trial tests a new treatment for children and adolescents with significant hair loss due to Alopecia Areata. The treatment likely helps the immune system stop attacking hair follicles, allowing hair to regrow. Oral tofacitinib has shown promising results in treating alopecia areata in children.
Janus Kinase (JAK) Inhibitor
Ruxolitinib for Alopecia Areata
Recruiting1 awardPhase 2
Bethesda, Maryland
This trial tests if ruxolitinib, a pill that calms the immune system, can help people with APECED and severe hair loss. The medication works by blocking overactive immune signals, which may reduce body attacks and promote hair regrowth. Ruxolitinib has shown promise in treating severe alopecia areata by inducing hair regrowth in patients.
Phase 3 Trials
Janus Kinase (JAK) Inhibitor
Upadacitinib for Severe Alopecia Areata
Recruiting1 awardPhase 3
Peterborough, Ontario
This trial is testing upadacitinib, a medication that may help people with severe hair loss due to alopecia areata. The drug works by stopping the immune system from attacking hair roots. Adolescents and adults with severe alopecia areata are participating to see if this treatment is safe and effective.
JAK Inhibitor
PF-06651600 for Alopecia Areata
Recruiting2 awardsPhase 3
Birmingham, Alabama
This trial is testing a new drug to treat alopecia areata, which is an autoimmune disease that causes hair loss. The trial is open-label, which means all patients will receive the active drug. There is also a sub-study evaluating the immune response to vaccines in patients who have received the drug for at least 6 months.
JAK Inhibitor
CTP-543 for Alopecia Areata
Recruiting1 awardPhase 2 & 3
Encinitas, California
This trial is testing CTP-543, a medication that may help people regrow hair by stopping the immune system from attacking hair follicles. It focuses on adults with chronic, moderate to severe alopecia areata. CTP-543 has shown promise in treating this condition.
Janus Kinase (JAK) Inhibitor
Baricitinib for Pediatric Hair Loss
Recruiting1 awardPhase 3
Birmingham, Alabama
This trial is testing baricitinib, a medication that may help treat severe hair loss. It targets children aged 6 to less than 18 years who have significant hair loss. The medication works by reducing the immune system's activity that causes hair loss.
Trials With No Placebo
Janus Kinase (JAK) Inhibitor
Ruxolitinib for Alopecia Areata
Recruiting1 awardPhase 2
Bethesda, Maryland
This trial tests if ruxolitinib, a pill that calms the immune system, can help people with APECED and severe hair loss. The medication works by blocking overactive immune signals, which may reduce body attacks and promote hair regrowth. Ruxolitinib has shown promise in treating severe alopecia areata by inducing hair regrowth in patients.
JAK Inhibitor
PF-06651600 for Alopecia Areata
Recruiting2 awardsPhase 3
Birmingham, Alabama
This trial is testing a new drug to treat alopecia areata, which is an autoimmune disease that causes hair loss. The trial is open-label, which means all patients will receive the active drug. There is also a sub-study evaluating the immune response to vaccines in patients who have received the drug for at least 6 months.
JAK Inhibitor
CTP-543 for Alopecia Areata
Recruiting1 awardPhase 2 & 3
Encinitas, California
This trial is testing CTP-543, a medication that may help people regrow hair by stopping the immune system from attacking hair follicles. It focuses on adults with chronic, moderate to severe alopecia areata. CTP-543 has shown promise in treating this condition.
Cellular Regenerative Treatment
Cell + Plasma Therapy for Hair Loss
Recruiting1 award8 criteria
Irvine, California
This trial is testing a new mixture of cells and plasma to see if it is safe and effective in treating hair loss. The mixture will be compared to a similar mixture and to a control group who will receive a standard treatment.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.